The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:1572 December 7, 1995 Number 23
NextNext

Angioedema Induced by the Angiotensin II Blocker Losartan

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Losartan (Cozaar, Merck) is a new, orally effective blocker of the angiotensin II receptor. The currently available angiotensin-converting–enzyme (ACE) inhibitors block the degradation of bradykinin, which is also metabolized by ACE. The accumulation of potent vasodilator kinins is believed to be the cause of cough and angioneurotic edema induced by ACE inhibitors. Because losartan does not have ACE activity, it would not be expected to increase bradykinin levels.1 The drug has therefore been advocated as being potentially free of these adverse effects. However, angioneurotic edema did occur in 1 patient among 4058 treated.1 We report another case . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.